Over 1.4 billion yuan! 7 biopharmaceutical companies announce completion of financing

"
Pharmaceutical Network Industry Dynamic" Securities Times data statistics show that on July 6, a total of 1268 shares were financed net purchase, the net purchase amount of more than 10 million yuan has 737, of which 85 net financing purchase amount of more than 100 million yuanThe author notes that in the field of biomedicine, in the recent year, there have also been a number of biopharmaceutical enterprises announced the completion of financingKai Paul BiologicalJuly 7 news, Hangzhou Kai Paul Biotech Co., Ltdannounced the completion of 100 million yuan B round of financing, the current round of financing will be used to accelerate the development pipeline to promote the pre-tech board registered listingOne of the company's core products, "Seven Autoantibodies of Lung Cancer", was successfully launched in 2015, becoming the first kit approved by the State Drug Administration for blood testing for lung nodules and early lung cancer, changing the traditional "single CT imaging dimension" lung cancer screening model in ChinaScreening of high-risk populations through molecular biomarkers such as serum antibodies to lung cancer, accurate screening, reducing screening costs, and improving screening efficiency and profitabilityChangfeng Pharmaceuticalsrecently, inhalation preparation pharmaceutical company Changfeng Pharmaceuticals announced the completion of 360 million yuan F round of financing, the current round of investors for Boyuan Capital and CICC Qichen, with the investors including CICC Qide, SAIC Hengxu, Jinpu merger and acquisition fund, Watson Investment, old shareholders Feijun Capital, Yuanming Capital and so on continue to increase their holdingsit is understood that Changfeng Pharmaceuticals has just announced on January 2 this year that it has completed the 630 million yuan E round of financing, two rounds of financing scale of nearly 1 billion yuanThe company's products in research mainly for respiratory inhalation preparations, covering asthma, chronic obstructive pulmonary disease, allergic rhinitis and other therapeutic areasAnd Meta biologicalrecently, and Meta-bio announced the completion of about 200 million yuan Pre-C round of financing, mainly used for the company layout to start the port large-scale precision industrial park construction, the introduction of overseas high-end talent, the development of gene therapy carrier new technology, new technology, etc, which will further expand the company's advantages in the domestic gene therapy CRO / CDMO subdivision field, better meet the growing domestic gene therapy and cell therapy on the recombinant virus carrier all-round demand, but also for the company to continuously enhance THE CDMO/ CMO service capabilities data show that the company is the leading domestic life science basic research, gene therapy drug incubation, clinical-grade recombinant virus industrialization preparation of the three major development directions of high-tech enterprises 　Xingyuyuan recently announced the completion of the multi-million dollar Pre-A round of financing, will be mainly used for the expansion of the talent team, the expansion of high-throughput laboratory and the promotion of cooperative drug research and development pipeline The company is a bio-high-tech company that combines artificial intelligence (AI) with biophysics for drug research and development Focus on macromolecular drug development, especially in the field of tumor immunotherapy On June 28, Lianchuan Bio
announced the completion of a total of 115 million yuan of B-round financing This round of financing will be used for the development of autonomous gene capture platform and gene synthesis platform, as well as its technical transformation and market development in the field of clinical gene detection data show that Lianchuan Bio is a genomics and precision medicine company, has built a national GMP standard sedituated gene testing reagents production base, has passed the ISO13485 quality system certification On June 29, Soyuan Bio
announced the completion of a C-round financing of RMB590 million It is reported that this round of financing will be used for the international multi-center clinical trials, to meet the needs of post-clinical trial funding data show that Soyuan Bio is an innovative enterprise that helps the international clinical pioneer in the research and development of new drugs in the late clinical period Currently has a global interest in six products that have been developed into late clinical care in the field of oncology and mental disorders, including one oncology drug DB102 has started and conducted an international multi-center clinical Phase III trial, and has completed more than 90% of patients into the group On June 24th, Yan'an Biological announced that 70 million yuan of B-round financing had been completed This round of financing will be mainly used to promote the layout of single-cell histological diagnostic platform with mass spectrometry technology as its core, accelerate the registration and declaration and commercialization of the system as a clinical diagnostic product, and further develop research and development cooperation with clinical experts and innovative pharmaceutical companies Founded in 2016, the company is a medical technology company focused on research and development of single-cell precision diagnostic technology and clinical applications.